Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer.
Couderc AL, Ninove L, Nouguerède E, Rey D, Rebroin M, Daumas A, Tomasini P, Greillier L, Salas S, Duffaud F, Dahan L, Duluc M, Garcia ME, Pluvy J, Chaléat S, Farnault L, Venton G, Fourié T, Nurtop E, de Lamballerie X, Villani P, Charrel R, Correard F. Couderc AL, et al. Among authors: duffaud f. J Geriatr Oncol. 2022 Jul;13(6):850-855. doi: 10.1016/j.jgo.2022.05.002. Epub 2022 May 16. J Geriatr Oncol. 2022. PMID: 35589542 Free PMC article.
Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, Monjanel-Mouterde S, Baciuchka-Palmaro M, Dupuis C, Yang C, Balti M, Lacarelle B, Duffaud F, Durand A, Favre R. Salas S, et al. Among authors: duffaud f. Ther Drug Monit. 2006 Aug;28(4):532-9. doi: 10.1097/00007691-200608000-00008. Ther Drug Monit. 2006. PMID: 16885721 Clinical Trial.
Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial.
Salas S, Baumstarck-Barrau K, Alfonsi M, Digue L, Bagarry D, Feham N, Bensadoun RJ, Pignon T, Loundon A, Deville JL, Zanaret M, Favre R, Duffaud F, Auquier P. Salas S, et al. Among authors: duffaud f. Radiother Oncol. 2009 Dec;93(3):503-9. doi: 10.1016/j.radonc.2009.05.016. Epub 2009 Jun 11. Radiother Oncol. 2009. PMID: 19524315 Clinical Trial.
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C. Ciccolini J, et al. Among authors: duffaud f. J Clin Oncol. 2010 Jan 1;28(1):160-5. doi: 10.1200/JCO.2009.24.4491. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933910
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C. Yang CG, et al. Among authors: duffaud f. Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56. doi: 10.1007/s00280-010-1282-4. Epub 2010 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 20204365 Clinical Trial.
212 results